Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

AstraZeneca and Abbott discontinue development of Certriad for mixed dyslipidemia

Dec. 24, 2010

Leo Pharma divulges new positive modulators of calcium-sensing receptor

Dec. 24, 2010

Amylin submits initial sections of rolling BLA for metreleptin

Dec. 23, 2010

Isis begins phase I ISIS-APOCIIIRx trial to treat hypertriglyceridemia

Dec. 23, 2010

Novo Nordisk and Emisphere to develop oral insulin for diabetes

Dec. 23, 2010

Preclinical data presented on Radius Health's SARM RAD-140

Dec. 23, 2010

Vivus submits MAA to EMA for obesity treatment Qnexa

Dec. 22, 2010

EMA provides update on safety review for somatropin-containing medicines

Dec. 21, 2010

FDA approves folate-containing oral contraceptive Safyral

Dec. 21, 2010

Amarin provides update on phase III ANCHOR trial

Dec. 20, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.